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Summary To test its diagnostic potential and sensitivity in paediatric malignancy, serum NSE was measured
at diagnosis in 191 children with solid tumours and 25 with acute leukaemia. In stages 1+II, III+IV and IVs
neuroblastoma median levels were 18.0, 91.0 and 24.0 ngml - I respectively. For Wilms' patients, median
values for stages I, II, III and IV disease were 16.6, 18.0, 29.0 and 47.0ngml-1 respectively. High levels of
NSE were also found in patients with other types of tumour. Children in clinical remission after treatment for
neuroblastoma invariably had normal NSE levels (mean+s.d.=9.2+3.0ngml-1) even though the majority
had radiologically identifiable residual disease. The values rose when relapse was radiologically or clinically
obvious. We conclude (a) that, though levels of > 100 ng ml- are highly suggestive of advanced
neuroblastoma, caution should be exercised in using serum NSE as a diagnostic test in children with cancer
and (b) that serum NSE levels are not a sensitive index of residual neuroblastoma in patients, with initially
elevated levels, that are receiving treatment.
Enolase, (2-phospho-D-glycerate hydrolyase or phospho- The serum samples were obtained from patients with solid
pyruvate hydratase EC 4.2.1.11), a glycolytic enzyme, is tumours or acute leukaemia attending our hospitals
present in the brain in three isoforms (xx, a- and 'it). The o including additional material from a bank of serum obtained
form is synthesized by glial cells and most cells in the body, at diagnosis from children with a variety of solid tumours
this isoform is called non-neuronal enolase (NNE) attending The Hospital for Sick Children, London. The
(Marangos et al., 1980). The y form is known as neuron diagnoses of all the tumours in this series were based on
specific enolase (NSE) as it is produced by neurons and histological examination. All samples were stored at -20-C.
neuroendocrine cells, and thought at one time to be specific Immunoreactive NSE is stable at least up to 4 years at this
for these cell types, subsequently its demonstration in many temperature (Zeltzer et al., 1986), the distribution of NSE
other cell types has indicated it lacks the specificity that the values from samples stored >2 years being similar to that of
name implies (Schmechel, 1985). NSE is one of several samples analysed soon after collection. The controls were: (a)
markers characteristic of cells that make up the amine Children awaiting cardiac surgery at the Hospital for Sick
precursor uptake and decarboxylation (APUD) system. Children, London; (b) children with non-malignant diseases
Others include the peptide hormones and L-dopa attending the Service d'Hematologie Pediatrique, Cliniques
decarboxylase which are often expressed by tumours that Universitaires St. Luc, Brussels. Neuroblastomas were staged
have APUD characteristics, including small cell carcinoma of according to Evans et al. (1980). Stage IV neuroblastoma is
the lung, neuroblastoma, phaeochromocytoma and a variety defined as remote disease involving the skeleton, organs, or
of rarer 'small round cell' tumours. Serum NSE levels can be distant lymph nodes and stage IVs defined as patients with
raised in neuroblastoma and have prognostic significance localised tumour who would otherwise be stage I and II but
(Ishiguro et al., 1983; Notomi et al., 1985; Zeltzer et al., who have remote disease confined to one or more of the
1983; 1986). However, the experience of the Children's following sites: liver, skin or bone marrow (without radio-
Cancer Study Group in the United States, indicates NSE is graphic evidence of bone metastases on complete skeletal
probably not particularly useful for monitoring the treatment survey). Wilms' tumours were staged according to D'Angio
of neuroblastoma as recurrence can occur without a rise in et al. (1980).
the serum NSE level (Zeltzer et al., 1986). Comparisons between the groups were analysed first by
The earlier reports on serum NSE in solid tumours in Kruskal-Wallis one way analysis of variance. Differences
children were limited to a few centres working with between groups were defined by Mann-Whitney test for
laboratories where an assay had been produced. The skewed distributions.
introduction of commercial NSE assay kits has provided a
wider opportunity to evaluate the measurement of serum
NSE in paediatric oncology. The NSE tests reported in this Results
study use an antiserum directed against the jy sub-unit, it
reacts with the o' and y7' isoforms both of which are present
in the serum. (Ishiguro et al., 1983). In this paper we have The range of NSE levels in the controls was
described our experience of applications of commercial NSE 3.2-20.4ngmlV- (mean+s.d.= 10.6+4.5ngml-1) with a
tcsts in relation to the diagnosis of solid tumours in children normal distribution. The distribution of the NSE levels in
sndsmpin red the l dvel n with thofs in childre 191 children with solid tumours at the time of their and ompaed teleels ith hosein aute eukamia.presentation to hospital is shown in Table 1. The distribution
of serum NSF levels in 25 patients with acute leukaemia at
Materials and methods presentation is shown in Table II. The highest level
260ngml1 was observed in a patient with common acute
All the serum samples were assayed using the NSF-RIA kit lymphoblastic leukaemia (ALL). Inspection of the tables
obtained from Pharmacia AB, Uppsala, Sweden. NSF levels indicates that the selection of 25ngml- and 100ngml-1
in a sub-set of these samples were also measured by an provide useful cut off levels. Values of <25ngmV' included
enzyme-linked immunosorbent assay obtained from Amano those found in the majority of patients with tumours not of
Pharmaceutical Coy, Aichi, Japan. neural crest origin. However, a number of children with
Wilms' tumours, 6 cases of non-Hodgkin lymphoma, 2 renal
Correspondence: E.H. Cooper. adenocarcinomas, one Ewing's sarcoma and 4 cases of
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Table I Neuron specific enolase levels at presentation carcinoma (30 and 117 ngml1 respectively). Three of the 17
patients (17.6%) with renal tumours had NSE levels
Serum NSE ngml- > 100ngml-1 (Pritchard et al., 1987).
The sera from 14 Wilms' tumour patients and 21 neuro-
Tumour Number <25 25-50 51-100 >100 blastomas were also measured by an alternative NSE assay
Controls a 27 27 (NSE-EIA, Amano). The high levels in the Wilms' tumours
b 11 11 were confirmed. The Pharmacia and Amano assays had a
Neuroblastoma correlation coefficient of r=0.97 and a slope and intercept of
Stages I & II 9 6 1 1 1 y= 1.04x+ 1.305.
Stages III & IV 63 9 7 16 31 In view of the unexpectedly high levels of NSE in the
IVs 3 2 1 cases of Wilms' tumour, an immunohistological examination
Ganglioneuroma 4 4 was made for NSE reactive cells with negative results.
Retinoblastoma 4 4 Serum NSE levels were measured in 37 patients at various
Wilms' tumour times after starting treatment, these patients eventually
Stages I & II 15 13 2 attained a good partial or complete remission as definied by
Stages II & IV 14 5 3 4 2 Shafford et al. (1984). Chemotherapy usually was associated
Ewing's sarcoma 11 10 1 with a rapid reduction in the NSE level to < 15 ngml-1, but
Soft tissue sarcoma 23 19 3 1 in 23 patients with observations during the first 6-12 months
Other tumours 30 28 1 la after starting treatment the NSE levels were low (mean +s.d.
9.5 +3.0ngml- 1) when there was residual tumour, including
The 'other' tumours include the following: 2 ovarian; 5 teratomas; patients who had received chemotherapy but not been
5 hepatoblastomas; 2 malignant histiocytosis; 2 renal carcinomasa; treated by surgery at the time the sample was taken. Four
1 haemangiopericytoma; 1 phaeochromocytoma; 1 mesoblastic patients had a raised NSE level (25-40ngml-1) during
nephroma; 1 Schwanoma; 1 cerebral ependymoma; 1 hamartoma; treatment when there was evidence of residual disease In 1 melanoma; 1 granulosa cell tumour, 1 malignant histiocytosis; tratment whe thierew ec eto resida die N 1 medulloblastoma; 2 osteosarcomas, 1 hepatic haemangio 15 patients who achieved complete remission the NSE
endothelialoma, 1 Burkitt nasopharyngeal carcinoma. Controls levels were between 5.1-12.0ngml1 (mean+s.d.
(a): Hospital for Sick Children, London; Controls (b): Service 8.4+2.5 ngml 1). Serum NSE measurements were made in
d'Hematologie Pediatrique, Cliniques Universitaires St. Luc, 19 patients with neuroblastoma in relapse and ranged from
Brussels. 10.2 to 7,200ngmlP1, median 75ngmlF1; in two (10.5%)
the level was <25ngml-P, and in 6 (31.5%) it was
> 100ngml- .
Table II Neuron specific enolase at presentation
Acute leukaemia Discussion
Serum NSE ngml-'
Immunohistochemical studies of the distribution of NSE in
children's tumours has demonstrated widespread diffuse
Acute lymphoblastic 23 20 2 - 1 reactivity in all types expressing a neural phenotype,
Acute myeloblastic 2 1 1 including neuroblastoma, neuroganglioma, medulloblastoma,
phaeochromocytoma (Triche et al., 1985; Odelstad et al.,
1981) and retinoblastoma (Kivela, 1986). By contrast, focal
staining for NSE has been observed in Ewing's sarcoma,
rhabdomyosarcoma and lymphoma (Triche et al., 1985) and
>25 ngml' The level of >100 ngml1 was chosen as a in several tumours in adults including renal cell carcinoma
second discriminant because it has been shown to have (Vinores et al., 1984). Biochemical analysis has shown that
prognostic significance in stage IV under 1 year NSE accounts for 28% to 62.5% of the enolase activity of
neuroblastoma; levels >100ngml1 carry a worse prognosis neuroblastoma, but only 1% to 4.5% of that in Wilms'
(Zeltzer et al., 1986). tumours (Odelstad et al., 1982). Fractionation of the enolase
Mean NSE levels in patients with neuroblastoma and indicated neuroblastomas contained the ay, and yy forms but
Wilms' tumour differ significantly (P>0.0001) and both in Wilms' tumours and gliomas the aa was the dominant
show a marked skew distribution, whilst those in the form with only a trace of ay and no yy (Odelstad et al., 1982;
remaining groups of patients had similar NSE distributions Beemer et al., 1984; Ishiguro et al., 1983).
with far less skewness. The analysis of variance showed that Our results in children with neuroblastoma and ganglio-
there were highly significant differences between the groups neuroblastoma mirrored those previously reported (Ishiguro
(P=0.0001). When the analysis was restricted to the et al., 1983; Notomi et al., 1985; Zeltzer et al., 1986). We
lymphoma, Ewing's sarcoma, soft tissue sarcoma, 'other have confirmed the direct association between stage and
tumour' and control groups significant differences were still serum NSE levels (Zeltzer et al., 1986) and that patients with
present (P=0.0092). The levels of NSE in Ewing's tumour stage IVs disease have relatively low NSE values. Although
and 'other tumour' groups were significantly increased the majority of them have residual disease readily
compared to the controls (P=0.002, and 0.009 respectively). identifiable by radiological imaging methods, nearly all
In 72 patients with neuroblastoma before treatment 57 patients in clinical remission after chemotherapy with a good
(59%) of them had a serum NSE >25ngml1 and in 31 partial or complete response according to the criteria of
(44%) the value was > 100ngml 1. Levels in patients with Shafford et at. (1984) had NSE levels similar to controls,
stage IVs were low compared to those with true stage IV whatever the initial stage. The sensitivity of the test is
disease (Evans et at., 1971). The median levels in stages I & therefore limited.
II, III & IV, and IVs were 18.0, 91.0 and 24.0OngmlP- By contrast, the high levels of serum NSE we have
respectively. Four cases of ganglioneuroma had NSE levels identified in advanced Wilms' tumours and renal carcinoma
of 9.9, 14.1, 15.4 and 21.3ngml1 respectively. Serum levels confirmed using two independent assays cannot be easily
in the two other tumours of APUD cell origin in this series - explained and have not been reported by other investigators.
both were phaechromocytomas - were 22.4 and 16.6ngml 1. As previously reported histological sections did not show
Nine (64%) out of 14 of patients with stages III & IV any NSE reactivity and our own studies were also negative.
Wilms' tumour had NSE levels >25ngml-1 and raised Haimoto et at. (1986) have demonstrated that the loops of
levels were also observed in two cases of renal adeno- Henle and renal collecting ducts normally contain highSERUM NEURON-SPECIFIC ENOLASE IN CHILDREN'S CANCER 67
concentrations of NSE. The proximal tubules contain
a enolase. In renal carcinoma, thought to originate from
proximal tubules, there is probably an induction of the
y enolase production. In Haimoto's series 20 (49%) out of
patients had a raised serum NSE. Though there is no
evidence for the induction of y enolase synthesis in Wilms'
tumour tissue, it is possible that the renal damage caused by
the tumour might lead to release enolase (NSE) into the
circulation, but this does not explain why only patients with
stages III & IV disease showed this phenomenon. We have
observed two adults with renal carcinoma and high NSE
levels 60 and 92ngmml1 (unreported data) and in one child
with a benign cystic renal lesion the serum NSE was
45 ngml-1, but renal failure is not a cause of a raised NSE
(Ruibal et al., 1985). The association between renal tumours
and a raised serum NSE is firm, but the mechanism could
vary from one disease to another. The practical aspect of
this finding is that caution must be exercised in using a
serum NSE level in differential diagnosis of Wilms' tumour
and neuroblastoma. It is only when the NSE is
> 100 ng ml- that the test is a strong indicator of neuro-
blastoma, 32 (88%) out of 36 patients with an NSE level
> 100 ngml - had neuroblastomas, the others included I
ALL, I renal carcinoma and 2 Wilms' tumours.
Zeltzer et al. (1986) reported the NSE levels in 10 cases of
acute leukaemia in children, range 12-286 ngml-', the
highest level was in a case of ALL; in 10 cases of Ewing's
sarcoma the levels were 8-47 ngml- 1. A single case of
hepatoblastoma had an NSE level of 176 ngml- 1. Our
findings show a similar incidence of occasional raised NSE
levels in most of the tumour groups not of neuroendocrine
origin.
Our experience, from a large series of patients, has
confirmed that serum NSE levels can be raised in a variety
of childhood tumours, thus limiting the value of this test in
diagnosis. Our experience of serial measurements in patients
with neuroblastoma during treatment is limited but it would
appear that levels can return to normal early during chemo-
therapy, at a time when there is still clinical and radiological
evidence of residual disease. Thus, the test is not particularly
sensitive and it is doubtful whether serial serum NSE
measurements will be more valuable than serial catechol-
amine levels in monitoring of children on treatment (c.f.
Dranoff & Darell, 1984).
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